Detecting EGFR alterations in clinical specimens-pitfalls and necessities

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Early-stage lung cancer diagnosis and treatment are critical.
• Epidermal growth factor receptor (EGFR) mutations are key therapeutic targets.
• Limited data exists on EGFR mutation frequency in Southern Swedish lung cancer patients.

Purpose of the Study:

• To investigate the frequency and spectrum of EGFR mutations in early-stage lung cancer in Southern Sweden.
• To evaluate the utility of mutation-specific immunohistochemical (IHC) antibodies versus PCR-based methods.
• To assess the correlation between EGFR protein expression, gene copy number, and mutational status.

Main Methods:

• Analysis of 350 early-stage lung cancers (adenocarcinomas, squamous cell carcinomas, large cell carcinomas).
• Utilized immunohistochemistry (IHC) with mutation-specific antibodies (L858R, del E746-A750) and mutation-specific PCR.
• EGFR sequencing performed on a subset of tumors to identify a broader mutation spectrum.

Main Results:

• EGFR mutations L858R and del E746-A750 were found in 10% of adenocarcinomas and <2% of squamous cell carcinomas.
• IHC showed intratumoral heterogeneity and discrepancies with PCR results.
• EGFR sequencing revealed a more diverse mutation spectrum than detected by mutation-specific antibodies.
• High total EGFR protein expression correlated with high gene copy numbers but not mutational status.

Conclusions:

• The EGFR mutation spectrum in Southern Swedish lung cancer is diverse, challenging the comprehensive coverage by mutation-specific antibodies.
• Intratumoral heterogeneity and discrepancies between IHC and PCR highlight limitations of mutation-specific antibody usage.
• Further optimization of diagnostic methods is needed for accurate EGFR mutation detection in lung cancer.